Our present study indicates that the IL-17A +197 G/A/T polymorphism (rs2275913) is associated with the risk of cancer in Asian populations and nongastrointestinal cancers.
Of them, IL-17 (-197G/A) polymorphism (rs2275913) was statistically significantly associated with risk of gastrointestinal diseases, especially for gastrointestinal malignancy and gastroduodenal diseases.
The pooled ORs with 95% CIs indicated that the IL-17A rs2275913G>A polymorphism was significantly associated with increased cancer risk (for A versus G: OR = 1.28, 95% CI: 1.16-1.41, P < 0.001, I (2) = 61.1%; for GA versus GG: OR = 1.12, 95% CI: 1.02-1.23, P = 0.015, I (2) = 27.8%; for AA versus GG: OR = 1.71, 95% CI: 1.38-2.41, P < 0.001, I (2) = 69.6%; for GA + AA versus GG: OR = 1.23, 95% CI: 1.13-1.34, P < 0.001, I (2) = 6.4%; for AA versus GG + GA: OR = 1.62, 95% CI: 1.27-2.07, P < 0.001, I (2) = 81.4%).